The objective of this review was to evaluate the effectiveness of relaxation to lower high blood pressure. We searched electronic bibliographic databases and grey literature to identify randomized controlled trials comparing relaxation therapies with no active treatment or sham therapy, enrolling adult participants with raised systolic blood pressure (SBP) X140 mm Hg or diastolic blood pressure (DBP) X85 mm Hg and follow-up X8 weeks. Twenty-five trials with up to 5 years follow-up, assessing 1198 participants, met our inclusion criteria and were metaanalysed. Overall, relaxation resulted in small, statistically significant reductions in SBP (mean difference: À5.5 mm Hg, 95% CI: À8.2 to À2.8) and DBP (mean difference: À3.5 mm Hg, 95% CI: À5.3 to À1.6) compared to the control. Substantial heterogeneity between trials (I 2 470%) was not explained by duration of follow-up, type of control, type of relaxation therapy or baseline blood pressure. The 9 trials that reported blinding of outcome assessors found a nonsignificant net reduction in blood pressure (SBP mean difference: À3.2 mm Hg, 95% CI: À7.7 to 1.4) associated with relaxation, as did the 15 trials comparing relaxation with sham therapy (SBP mean difference: À3.5 mm Hg, 95% CI: À7.1 to 0.2). Adequate randomization was confirmed in only seven trials and concealment of allocation in only one. In view of the poor quality of the included trials and unexplained variation between trials, the evidence in favour of a causal association between relaxation and blood pressure reduction is weak. Some of the apparent benefit of relaxation was probably due to aspects of treatment unrelated to relaxation.
Introduction
Although there is substantial evidence that shortterm stress can lead to elevated blood pressure (BP), 1,2 its relevance to sustained hypertension remains unclear. 3 No strong epidemiological evidence exists for such an association. Furthermore, the physiological mechanisms that might link stress to the development of sustained hypertension are unclear. Although short-term BP elevation can be attributed to sympathetic nervous system activity corresponding to the body's 'fight-or-flight' alarm reaction, long-term changes may be perpetuated by vascular remodelling and endothelial dysfunction. 1, 2 A variety of therapies that aim to reduce stress and encourage relaxation have been investigated as methods to treat hypertension. The relaxation response is the opposite of the fight or flight phenomenon; it reduces BP and lessens the harmful effects of stress. 4 It may be elicited by repeating a word or phrase, while adopting a passive attitude and decreased muscular tone. 5 Autogenic training aims to elicit the relaxation response through focusing on physical sensations of, for example, breathing or heartbeat, assisted by self-suggestion. 6, 7 Cognitive therapy aims to change irrational thought processes behind problematic emotions. 8 Behavioural therapy uses reinforcements (for example, rewarding or not rewarding specific behaviours) to modify behavioural responses to stress. 8 Meditation focuses an individual's attention while calming their thoughts. 8 Guided imagery focuses on calming images with the goal of achieving relaxation. 8 Biofeedback trains the individual to alter a physiological response through receiving visual or auditory feedback. 8 Progressive muscle relaxation encourages relaxation through awareness of the sensation in the main muscle groups and is often accompanied by breathing exercises and guided imagery. 9 Breathing exercises encourage slow and regular breathing, which may directly influence the cardiovascular system. 10 Yoga usually includes stretching, postural and breathing exercises and meditation. 11 Previous systematic reviews of relaxation therapies for treating hypertension 5, 6, 12, 13 provided conflicting evidence. Furthermore, recent metaanalyses 6, 13 were restricted to autogenic training and biofeedback, respectively, and only one of these meta-analyses 12 was restricted to studies with a minimum length of follow-up (6 months). As treatment for hypertension is likely to be a life-long process, short-term studies may not be relevant to establishing long-term benefits. Finally, some types of relaxation therapies may be effective in reducing BP, whereas others may not. 5 Therefore, there is a need for an up-to-date review of all relaxation treatments for lowering raised BP, which excludes short-term studies and explores possible differences between the effects of different therapies.
The aim of this review was to summarize the evidence about the benefits and harms of relaxation therapies for patients with primary hypertensionhigh BP with no identifiable cause 14 -to inform decisions about recommendations for treatment.
Methods
The methods have been reported in detail in a Cochrane review and are summarized below. 15 
Inclusion criteria
We included randomized controlled trials (RCTs) of a parallel design and at least 8 weeks duration that enrolled adults over 18 years, with elevated BP: a minimum of 140 mm Hg for systolic blood pressure (SBP) or 85 mm Hg for diastolic blood pressure (DBP), without a known primary cause. RCTs were eligible if they compared any intervention designed to promote relaxation with a control: either (i) no active treatment or (ii) sham therapy designed to control for non-specific features of the treatment setting.
Exclusion criteria
We excluded studies which evaluated a combination of relaxation therapies and other interventions such as diet or exercise, studies of pregnant women, studies including participants on antihypertensive medication, which was allowed to vary during the course of the study and studies that did not report results for participants according to the treatment groups to which they were assigned.
Outcomes of interest
The primary outcome measures of interest were: death from all causes; coronary heart disease events; cerebrovascular events; SBP and DBP at end of follow-up, preferably measured in clinic. However, as most included studies were small and short-term, few reported deaths or cardiovascular events. The review, therefore, focuses on BP as an outcome.
Secondary outcome measures were: adverse events, categorized as uncontrolled hypertension and other; total withdrawals from treatment; withdrawals from treatment due to adverse events, categorized as uncontrolled hypertension and other. 16, 17 and the reference lists of included RCTs and of meta-analyses [5] [6] [7] 12, 13, [18] [19] [20] identified from the searches. There was no language restriction.
All titles and abstracts retrieved by electronic searching were screened independently by two reviewers, and studies which clearly did not meet the inclusion criteria were excluded. Copies of the full text of potentially relevant references were obtained and their eligibility was assessed.
Data abstraction
Methodological quality of included trials was assessed independently by two reviewers using the following criteria: adequacy of randomization; concealment of allocation of assigned treatment from treatment providers and patients; blinding and loss to follow-up. Two reviewers independently abstracted endpoint data and data describing the trial characteristics using a pre-specified form.
We categorized the components of active interventions as: biofeedback; cognitive/behavioural therapy (including meditation, yoga and guided imagery); progressive muscle relaxation or autogenic training.
Differences were reconciled by discussion or consultation with a third reviewer.
Statistical methods
The findings of included trials were aggregated in meta-analyses using Review Manager 4.2.8 21 and Stata 9.2. 22 The weighted mean difference method was used to estimate the pooled mean difference in SBP and DBP between relaxation and control groups, using a random effects model. 23 Heterogeneity between trials was assessed using the I 2 statistic. 24 Funnel plots were examined to assess the potential for publication bias. 25 Sensitivity analyses were performed excluding poor quality trials. Sub-group analyses were performed grouping trials into pre-specified categories.
Adverse events and withdrawals from treatment were aggregated in meta-analyses, using random effects models 23 to calculate pooled risk differences.
Results
Description of studies Identification of included studies. The search strategy found 2404 potentially relevant references, of which we excluded 2260 following electronic screening ( Figure 1 ). We retrieved full copies of 144 references, describing 134 studies, for detailed evaluation, of which we excluded 105. The remaining 29 RCTs met our inclusion criteria but we excluded four RCTs from the primary meta-analysis because of missing standard deviations. [26] [27] [28] [29] Three of these were included in a sensitivity analysis by imputing standard deviations; 27-29 one could not be included in any meta-analysis as neither the numbers of participants enrolled nor the number assessed at the end of follow-up were reported for all intervention groups. 26 These excluded trials are described in detail elsewhere. 15 Design of trials. The 25 RCTs included in the primary meta-analysis enrolled 1419 participants in relaxation and control arms, of whom 1198 were assessed; some trials included other arms which were not considered in this review. 30, 31 One trial randomized communities rather than individuals. 31 Participants. The number of participants in each trial ranged from 16 to 171 (median: 43). There was substantial heterogeneity between trials in the characteristics of the participants enrolled. Entry criteria varied between trials, and the average baseline SBP of participants ranged between trials from 130 to 164 mm Hg (median: 144, inter-quartile range: 139-150 mm Hg) and the corresponding DBP from 86 to 109 mm Hg (median: 92, inter-quartile range: 89-97 mm Hg). Thirteen trials enrolled a mixture of participants who were and were not being treated with antihypertensive medication; [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] nine trials enrolled only participants who were not receiving antihypertensive medication, [43] [44] [45] [46] [47] [48] [49] [50] [51] although two of these trials enrolled participants who had previously been on medication; 45, 47 one trial enrolled only participants who were receiving antihypertensive medication 52 and two trials did not specify the medication status of participants. 53, 54 One trial enrolled only participants with a 'Type A' personality: a tendency to anger and hostility. 44 Four trials were carried out in settings relevant to routine clinical care: a worksite, 43 primary care practices; 36, 40 participant's own home. 31 Other trials delivered the interventions in settings which were more appropriate to research. Participants were enrolled through referrals from primary care physicians, 32 All trials reported gender and 63% of the participants were male subjects. The overall mean age, reported in all trials except two, 40, 54 was 47 years (range: 18-73 years). Only six trials reported ethnicity and in these 84% of the participants were white. 35, 38, 39, 42, 45, 52 Ten trials were conducted in the USA, three in the UK, two in Canada, two in Israel, two in Spain, one in the Netherlands, one in New Zealand, one in the USSR, one in Taiwan, one in India and one in Venezuela.
Treatments
Active interventions. Three trials had multiple treatment arms. 32, 34, 44 Several trials combined components from several types of relaxation therapies in one active treatment arm. Relaxation interventions included: progressive muscle relaxation (16 trials) 30, 31, [34] [35] [36] [37] 39, 40, 42, 43, 46, 47, 48, [51] [52] [53] ; biofeedback (12 trials) 32, 34, 35, [37] [38] [39] [40] [41] 45, 46, 48, 52 ; autogenic training (6 trials) 33, 35, 38, 39, 49, 51 and cognitive or behavioural therapy or meditation (11 trials). 32, 36, 37, 40, 42, 44, 46, [49] [50] [51] 54 Within these categories, interventions were heterogeneous. Biofeedback included biofeedback of heart rate, 32 BP, 34 DBP and electrocardiogram, 35 forehead 41 It was generally used in combination with progressive muscle relaxation, sometimes also with cognitive and behavioural therapy, but in one trial it was used with autogenic training alone 38 and in one trial it was not combined with any other therapy. 41 Cognitive and behavioural therapies included anger control, 32 40 Most trials which taught progressive muscle relaxation encouraged participants to practise at home, often with the help of taped instructions; 31, 35, 39, 40, 43, 46, 47, 51, 53 some trials also encouraged participants to practise these relaxation techniques in stressful situations. 36, 40, 47 Relaxation therapies were delivered to participants either in a group setting 32, 35, 39, 40, [42] [43] [44] [45] [46] [51] [52] [53] or individually; 30, 31, 36, 37, 41, [47] [48] [49] in five trials the delivery setting was unclear. 33, 34, 38, 50, 54 The median duration of treatment was 8 weeks (range: 5-26 weeks).
Controls. Three trials had multiple control arms. 35, 46, 50 Control groups received sham therapy (15 trials) or no active intervention (14 trials).
The sham therapies used varied considerably between trials: most were some form of group therapy; in some trials the sham therapy was designed to mimic all the components of the active intervention except that which the investigators believed to be effective; in other trials it was less specific. Sham therapy variously included mild physical exercise; 30, 37, 49 biofeedback of galvanic skin resistance; 37, 42 sham biofeedback of BP; 35 encouragement of relaxation; 34, 46, 51, 53 counselling on stress;
26,51,52 education on hypertension; 26, 43, 51 meditation without use of a mantra; 50 listening to synthesized music; 41 lectures to encourage anticipation of reduction in BP 32 and non-specific support therapy. 48 Hence, some trials used sham therapies which were similar to the active interventions in other trials.
Outcomes
Death, myocardial infarction and stroke. Only one trial, enrolling 134 participants, reported deaths, myocardial infarctions and strokes and only one of each of these events occurred, in the relaxation, control and relaxation groups, respectively. 40 Relaxation was not associated with any significant difference in the risk of death, myocardial infarction or stroke (RR comparing relaxation with control ¼ 3.2, 95% CI: 0.1 to 76, 0.4, 95% CI: 0.02 to 8.8 and 3.3, 95% CI: 0.1 to 79, respectively).
Blood pressure. Final BP was measured in clinic in all trials except one, in which it was measured at home; 31 in most trials the participant was seated; in nearly all trials final BP was averaged over two or more readings; about half the trials measured BP using a mercury sphygmomanometer and about half used an automatic device.
Adverse events. Seven trials reported, by treatment arm, the numbers of participants who experienced adverse events. 40, 43, 45, 47, 48, 50, 51 These were usually uncontrolled hypertension, but also included angina, heart failure, kidney damage, thrombosis of retinal vessels, a broken rib, cancer, chest pain, drug complications and an unspecified medical problem. The criteria used for uncontrolled hypertension were not consistent between trials.
Withdrawals. Fourteen trials reported the number of withdrawals from treatment by treatment arm. 30, 32, 34, 37, 38, 41, [43] [44] [45] [46] 49, 51, 52, 54 A further four trials reported overall withdrawal from treatment. 36, 37, 40, 42 Withdrawals due to adverse events. Five trials reported the number of withdrawals due to adverse events. 43, 45, 47, 48, 51 Additionally, three trials reported no withdrawals in either arm 35, 46, 52 and one trial reported the total number of withdrawals due to adverse events. 49 Follow-up. The median duration of follow-up was 20 weeks (range: 8 weeks to 5 years); 13 trials had follow-up of less than 6 months and 12 trials had follow-up of 6 months or more.
Methodological quality of trials included in primary meta-analysis Although all 25 trials included in the primary metaanalysis claimed to be randomized, the method of randomization was confirmed to be adequate in only seven trials. 35, 40, 41, 43, 47, 49, 51 Concealment of allocation could be confirmed as adequate in only one trial. 40 Nine trials reported blinding of outcome assessors; [30] [31] [32] 35, 41, 43, 48, 49, 52 one trial blinded both participants and treatment providers. 41 The remaining trials did not clearly report blinding.
Fourteen trials reported loss to follow-up by treatment arm and, in these, 15% of participants were lost to follow-up. 30, 32, 34, 35, 38, 41, 43, 45, 46, 48, 49, 51, 52, 54 If loss to follow-up was not reported, we assumed there was none.
Six trials which included participants receiving antihypertensive medication did not clearly report whether the investigators attempted to keep this medication unchanged throughout the trial. 26, 31, 33, 40, 42, 53 Four trials which attempted to keep antihypertensive medication constant excluded from analysis the few participants who altered their medication. 36, 39, 48, 50 Meta-analyses Primary meta-analysis of BP. Meta-analysis of 25 trials, assessing 1198 participants, found relaxation was associated with statistically significant reductions in both SBP (mean difference: À5.5 mm Hg, 95% CI: À8.2 to À2.8) and DBP (mean difference: À3.5 mm Hg, 95% CI: À5.3 to À1.6) compared to control (Figure 2 ). There was substantial heterogeneity for both SBP (I 2 ¼ 72%) and DBP (I 2 ¼ 75%). Funnel plots showed little evidence of publication bias (Egger's 25 p ¼ 0.47 and 0.26 for SBP and DBP, respectively), except that one very small trial showed an extremely large benefit of relaxation 54 ( Figure 3 ). Imputation of missing standard deviations for three trials, [27] [28] [29] confirmed the results of the primary analyses.
Sensitivity analyses excluding poor quality trials. One small trial, which did not confirm adequate randomization, concealment of allocation or blinding, reported a very large net reduction of 28/25 mm Hg in BP in the relaxation group and had substantial influence on the results. 54 Exclusion of this trial resulted in lower overall reductions in BP and less heterogeneity (SBP mean difference: À4.6 mm Hg, 95% CI: À6.9 to À2.2, I 2 ¼ 62%; DBP mean difference: À2.9 mm Hg, 95% CI: À4.5 to À1.3, I
2 ¼ 66%) (Figure 3 ).
Blinding of outcome assessors. In the nine trials, which reported blinding of outcome assessors, relaxation was not associated with any statistically significant reduction in either SBP or DBP compared to control. Heterogeneity remained substantial for both SBP and DBP.
Concealment of allocation. The one trial which reported adequate concealment of allocation compared an active intervention which combined progressive muscle relaxation and biofeedback with no intervention. 40 It enrolled 134 participants of whom 31 (23%) were lost to follow-up. Based on the reported changed scores, we estimated that relaxation was associated with statistically significant reductions in both SBP (mean difference: À12.0 mm Hg, 95% CI: À17.8 to À6.2) and DBP (mean difference: À4.1 mm Hg, 95% CI: À7.4 to À0.9) compared to control. However, participants in the relaxation group had a significantly higher baseline BP (145/89 mm Hg) than those in the control group (136/86 mm Hg). This baseline imbalance was thoroughly considered by the trial investigators and remained after including and excluding various sub-groups of participants and also when comparing BP readings taken prior to the baseline measurement. The investigators, therefore, carried out an analysis of covariance which adjusted for differences in baseline BP. This analysis found that relaxation was associated with net reductions in both SBP (mean difference: À7.3 mm Hg, 95% CI: À12.6 to À2.0) and DBP (mean difference: À2.2 mm Hg, 95% CI: À5.2 to 0.7), which were less marked than those which we found and statistically significant only for SBP.
Sub-group analysis by characteristics of trial. The net BP reductions obtained in the various sub- Figure 2 Forest plots corresponding to primary meta-analysis: estimated mean difference in systolic and diastolic blood pressure (SBP and DBP) between relaxation and control groups in each trial and overall effect. n(T), number of participants assessed in relaxation group; n(C), number of participants assessed in control group; SBP(T), DBP(T), final value or change score for SBP and DBP, respectively in relaxation group; SBT(C), DBP(C), final value or change score for SBP and DBP, respectively in control group; MD, mean difference in final blood pressure (or change in blood pressure) between relaxation and control groups; %wt, weight given to this trial in random effects meta-analysis. groups which were compared-short-term/longterm follow-up; sham therapy/non-intervention control; initial SBP above/below the median; initial DBP above/below the median; with/without each type of the relaxation therapy-were not significantly different. There was substantial heterogeneity within all sub-groups, except the sub-group of trials of relaxation with biofeedback using non-intervention controls, where heterogeneity was much lower (I 2 ¼ 24%) (Figure 4 ).
Duration of follow-up. Relaxation was associated with statistically significant reductions in SBP and DBP, both in the 13 trials with follow-up of less than 6 months and in the 12 trials with longer follow-up. Summary of overall effects of relaxation as estimated by primary meta-analyses, sensitivity analyses and sub-group analyses. N, number of included trials; n, number of participants assessed; WMD, weighted mean difference in final blood pressure (or change in blood pressure) between relaxation and control groups, estimated from random effects meta-analysis; I 2 , percentage of variation between trials that cannot be ascribed to sampling variation. * Some trials included multiple treatment arms and were included in both subgroups, with half of the control group participants being assigned to each sub-group.
Type of control. In the 15 comparisons of relaxation with a control group receiving sham therapy, relaxation was associated with a nonsignificant reduction in both SBP and DBP, whereas in the 13 comparisons with a control group not receiving any active intervention, it was associated with a larger, statistically significant reduction in both SBP and DBP.
When analysis was restricted to trials of relaxation with biofeedback, the eight comparisons with sham therapy showed a statistically significant reduction in SBP but a non-significant reduction in DBP, whereas the six comparisons with non-intervention controls showed statistically significant reductions in both SBP and DBP.
Initial blood pressure. Relaxation was associated with a statistically significant reduction in SBP in trials with initial SBP above or equal to the median (143.9 mm Hg), but not in others. In contrast, relaxation was associated with a statistically significant reduction in DBP both in trials with initial DBP above or equal to the median (92.4 mm Hg) and in those with initial DBP below the median.
Type of relaxation therapy. Meta-analyses were sub-grouped by comparisons with/without: biofeedback, cognitive and behavioural therapies, progressive muscle relaxation and autogenic training. In each sub-group-except relaxation with autogenic training-relaxation was associated with statistically significant reductions in both SBP and DBP.
Adverse events. Meta-analysis of uncontrolled hypertension, other adverse events, overall withdrawal from treatment, withdrawal from treatment due to uncontrolled hypertension and withdrawal from treatment due to other adverse events showed no significant difference between relaxation and control, with no heterogeneity between trials except for moderate heterogeneity in rates of overall withdrawal, largely due to the high rate of withdrawal (25%) in one trial ( Figure 5 ). 32 Loss to follow-up. In the 14 trials that reported loss to follow-up, meta-analysis showed no significant difference in the rate of loss to follow-up in the relaxation and control groups, but substantial heterogeneity between trials (I 2 ¼ 61%) ( Figure 5 ).
Discussion

Summary of findings
The primary meta-analysis of 25 RCTs assessing 1198 participants, with between 8 weeks and 5 years follow-up, found that interventions to promote relaxation were associated with a small, statistically significant reduction in both SBP and DBP. The random effects model which we used assumes that the effect of treatment differs in different populations but that these effects cluster around a mean: this estimated mean was a reduction in SBP of 5.5 mm Hg, (95% CI: 2.8 to 8.2) in participants receiving a relaxation intervention compared to those receiving a control intervention, with a concomitant reduction in DBP of 3.5 mm Hg (95% CI: 1.6 to 5.3). However, this estimated reduction of 5/3 mm Hg is probably an over-estimate of the effect of relaxation, as poor quality trials and comparisons with non-intervention controls generally over-estimate the effects of treatment.
When relaxation was compared with a sham therapy designed to mimic many of the components of the active treatment, but not the component thought to be effective the mean reductions in BP were smaller and not statistically significant. This is consistent with evidence that sham therapy alone can reduce a continuous outcome by between 0.2 and 0.5 standard deviations, 55 possibly due to therapeutic effects of the relationship between the participant and the treatment provider. Figure 5 Summary of primary meta-analyses, of adverse events and loss to follow-up: estimated overall risk difference between relaxation and control groups. N, number of trials reporting this information; n(T), number of events in relaxation group; n(C), number of events in control group; Tot(T), total number of participants assessed in relaxation group; Tot(C), total number of participants assessed in control group; RD, risk difference; I 2 , percentage of variation between trials that cannot be ascribed to sampling variation.
Most included trials were not of good quality. Inadequate concealment of allocation and lack of blinding are often associated with an exaggeration of the effects of treatment. 56, 57 Restriction to the nine trials (assessing 498 participants) that reported blinding of the outcome assessor resulted in mean reductions in SBP and DBP, which were smaller than those estimated by the primary meta-analysis and not statistically significant. The one trial (assessing 103 participants) that reported adequate concealment of allocation yielded results that were similar to the primary meta-analysis, but this trial did not blind outcome assessors.
Progressive muscle relaxation, relaxation with biofeedback and cognitive/behavioural therapies (such as teaching strategies for stress management and anger control) were all associated with statistically significant reductions in BP. As biofeedback was most frequently used in combination with progressive muscle relaxation, it is unclear which strategy or if only the combined strategies might be effective. We found little evidence that autogenic training reduced BP.
There was substantial heterogeneity between the estimated effects of relaxation in the various trials: between 70% and 80% of the variation between trials could not be explained by sampling variation. This heterogeneity does not appear to be due to bias in outcome assessment, as trials which blinded outcome assessors showed a comparable level of heterogeneity. Nor does it appear to be due to differential withdrawal from treatment or loss to follow-up, which was similar in treatment and control groups. Some possible factors duration of follow-up, type of control, initial BP and type of relaxation therapy were evaluated by sub-group analyses but, for each factor considered, the treatment effects in the sub-groups were not significantly different and moderate or substantial heterogeneity remained within each sub-group. Therefore, other, unidentified factors must largely explain the variation in findings of trials; this is not surprising, given the differences between the participants that they enrolled and the variety of active and control interventions used.
Funnel plots showed little evidence of publication bias. Rates of adverse events, withdrawal from treatment for any reason and withdrawal from treatment due to adverse events were similar in relaxation and control groups.
Strengths and weaknesses of review
The review was limited by the design of the included trials. As many trials used a combination of strategies to encourage relaxation, it is difficult to ascribe the outcomes either to specific components of the therapy or to their combined effect.
Some trials used components of interventions which were thought to be ineffective in lowering BP as sham therapy; other trials used similar strategies as active interventions, believing that it was useful to evaluate them.
External validity. Although lifestyle interventions for mild-to-moderate hypertension are likely to be of most interest to patients in primary care, only four trials were performed in community settings. Furthermore, fewer than half the trials recruited participants from community settings, through primary care physicians, the workplace or community screening. These participants usually had mild hypertension: many trials excluded patients with heart or renal disease, previous heart attacks or strokes, angina, diabetes and other serious medical disorders. None of the included trials reported the costs of implementing the intervention.
We divided the trials into two sub-groups in eight different ways and compared two outcomes (SBP and DBP) in each of these sub-groups. Therefore, many hypothesis tests were performed on the same set of trials and it is likely that one or two of these appeared statistically significant just by chance. 58 Use of antihypertensive medication. We excluded from our review 21 trials in which participants were taking antihypertensive medication, which could vary during the trial. If relaxation were effective in reducing BP and changes in antihypertensive medication were allowed, it is likely that a higher proportion of participants in the control group than the relaxation group would start on or increase their dose of antihypertensive medication. As antihypertensive drugs generally have a much more marked effect in lowering BP-typically of the order of 9/ 5 mm Hg for monotherapy 59 -than the effect postulated for relaxation, the inclusion of trials allowing such medication could result in an under-estimation of the real effect of relaxation. Although exclusion of such trials is likely to yield a less biased estimate of the effect of relaxation, it will also result in a wider confidence interval for the estimated effect due to the smaller number of included trials.
The difficulties of obtaining an unbiased estimate of the effect of relaxation treatment on BP when some participants use varying doses of antihypertensive medication could be addressed by modification to the design of trials. As it is unethical to deny patients BP lowering therapy if their BP remains persistently elevated above relevant guideline targets, trial protocols could exclude participants who they start on (or change their dose of) antihypertensive medication, but include their last BP measurements before exclusion. Alternatively, in large trials the efficacy of relaxation could be evaluated by survival analysis, treating starting on (or increasing) antihypertensive medication as a failure, with death and cardiovascular events as competing risks. 60 Comparison with other meta-analyses Four major meta-analyses of RCTs of relaxation therapies for hypertension have been conducted. 5, 6, 12, 13 These included different trials from our review because of the different time period for reporting of trials, different inclusion criteria, different judgements about whether individual trials were randomized, controlled and maintained any antihypertensive medication at a constant dose. They also used different methods of analysis: in particular, all analysed change scores, whereas we preferred final values, firstly because change scores are often chosen after observation of data to correct for 'unlucky' randomization, which results in a biased estimate of the effect of treatment 61 and, secondly, because they include less measurement error. 58 Three meta-analyses used weighted mean difference methods, 5, 12, 13 as our review did. One further systematic review meta-analysed the change scores in participants who received a relaxation intervention, but did not compare them with a control group. 20 Duration of follow-up. Ebrahim et al. 12 reported the findings of a fixed effects model used to aggregate the results of eight RCTs (six of which were included in our meta-analyses) that had at least 6 months follow-up and were conducted in hypertensive people aged 45 years or over; the threshold for hypertension was not defined. This metaanalysis found that relaxation was associated with a very small overall reduction of 1/1 mm Hg in BP. When we restricted our meta-analysis to 12 studies with at least 6 months follow-up, we also found small, but statistically significant, reductions in SBP and DBP (mean differences of À4.0 mm Hg, 95% CI: À7.6 to À0.5 and À1.9 mm Hg, 95% CI: À3.8 to À0.1, respectively).
Sham therapy/non-intervention controls. Eisenberg et al. 5 used a random effects model to aggregate the findings of 26 RCTs (12 of which were included in our meta-analyses) in people with DBP between 90 and 114 mm Hg. This meta-analysis found that relaxation therapies were superior to no treatment but not to a credible sham therapy, consistent with our findings. It also reported that trials in which baseline BP assessments were made during a period of a day or less found, on average, much larger reductions in BP than those with longer baseline periods.
Biofeedback. Nakao et al. 13 used a random effects model to aggregate the findings of 22 RCTs (11 of which were included in our meta-analyses) of biofeedback in people with BP over 140/90 mm Hg. This meta-analysis found that biofeedback was superior to no treatment but not to a credible sham therapy. We found significant overall reductions in both SBP and DBP for six trials that compared biofeedback with no treatment and similar reductions-significant for SBP but not for DBP-for eight trials that compared biofeedback with sham therapy, respectively. This difference in review findings is largely because of a different classification of the treatment and control groups in one trial, which reported very large reductions in BP (24/13 mm Hg) in the biofeedback group compared to the control group. 32 Autogenic training. Stetter et al. 6 used standardized mean difference methods which assume that all the variability between trials is due to differences in the measurement scale and that all trials have a similar amount of natural variation, which may not be true. As BP was measured on the same scale in all trials, we would argue that weighted mean difference methods should be preferred. Stetter's review aggregated findings of four RCTs (one of which was included in our meta-analyses), which evaluated autogenic training for mild-to-moderate primary hypertension and found that it significantly reduced BP immediately after treatment. However, based on three RCTs, Stetter's meta-analysis found as our review did that autogenic training had no significant effect on hypertension at the end of follow-up.
Biological plausibility
Acute rises in BP due to stress are thought to result from the action of adrenaline on the sympathetic nervous system. Furthermore, it has been suggested that adrenaline produced in the acute phase may be stored and released over a more sustained period. 3, 62 However, it is more plausible that chronic hypertension is mediated by factors that increase peripheral vascular resistance. Sustained increases in sympathetic nervous activity probably increase vascular resistance and lead to structural changes. Vascular remodelling, involving changes in blood vessel architecture, endothelial dysfunction and alterations in renal regulation of fluid balance, through the renin-angiotensin-aldosterone axis, are thought to be key components of this process. 2 In addition, modulation of glucocorticoid activity may also have a role. 3 It is likely that these systems are interlinked by complex feedback mechanisms.
Behavioural methods of relaxation therapy aimed to reduce BP through direct control of either the BP or the physiological processes involved in its regulation, whereas psychotherapeutic methods aimed to alter reactions to stress, thus, indirectly lowering BP. It is possible that stress reduction could work as a long-term strategy to decrease BP through effects on known BP regulatory mechanisms, for example through decreasing sympathetic nervous system activity or plasma concentrations of cortisol and aldosterone. 38, 63 Implications for research Despite calls since 1978 for improvements in the methodological quality of trials of relaxation for hypertension, 5, 12, 13, 34, 35, 37, 46, [48] [49] [50] 52, 53, 64 in particular for larger sample sizes from representative populations, longer baseline periods for screening of potential participants, control treatments that simulate the non-specific aspects of treatment, control of antihypertensive medication used by participants and blinding of outcome assessors, all the trials contributing to the evidence base were either methodologically flawed or failed to report methodological aspects adequately. Any future research should address the basic methodological issues, focus on community settings relevant to the management of mild-to-moderate hypertension and use a design that deals with possible changes in levels of antihypertensive medication in an appropriate way.
Clinical implications
In view of the poor methodological quality of the included studies, it is difficult to draw any definitive conclusions about the efficacy or lack of efficacy of relaxation techniques for primary hypertension. Furthermore, few studies have evaluated relaxation in community settings, which are relevant to routine implementation.
There was substantial variation between the effects of relaxation therapies in different populations and we were unable to identify the characteristics of patients in whom it was likely to be effective. Some of the reduction in BP apparently associated with relaxation is probably due to the non-specific effects of treatment, such as frequent contact with treatment providers. Progressive muscle relaxation, biofeedback and cognitive/behavioural therapies were the relaxation therapies most likely to be effective; there was little evidence that autogenic training was effective.
Even if relaxation results in a reduction in BP, the average reduction is probably less than 5/3 mm Hg. The studies included in this analysis were too small to detect any effect of relaxation therapy on morbidity (stroke and myocardial infarction) and mortality. In contrast, drug monotherapy can reduce SBP by about 9.1 mm Hg (95% CI: 8.8 to 9.3) and DBP by about 5.5 mm Hg (95% CI: 5.4 to 5.7), 59 is known to have sustained and consistent effects and to reduce morbidity and mortality. 65 However, as hypertension is a common condition, even small changes in BP in a large proportion of the population could prevent a large number of adverse cardiovascular outcomes. 66 As there is no good evidence that relaxation therapies result in meaningful reductions in BP, patients with mild-to-moderate hypertension who prefer non-pharmacological interventions may wish to consider alternative strategies-such as diet, exercise and restriction of intake of alcohol and salt-which result, on average, in small reductions in BP. [67] [68] [69] [70] 
